Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial
Zehra I. Uluturk, Anastasia Godneva, Sienna Walsh, Mallory Ledger, Eliza Chalmers, Jennifer R. Snaith, Tien-Ming Hng, Renee Richens, Krisztina Toth, Jennifer Evans, Jian Tan, Laurence Macia, Mark Danta, Eran Elinav, Eran Segal, Jerry R. Greenfield, Dorit Samocha-Bonet Communications Medicine
· Springer Nature
· 2026-11-19
· DOI: 10.1038/s43856-026-02009-3
Аннотация
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02009-3 People with type 2 diabetes can have too much sugar in their blood stream, which can lead to health problems. Metformin is a common medication for people with type 2 diabetes, but it does not always improve blood sugar levels. This study tests whether diet guidance, based on an individual’s data, could reduce blood sugar spikes after meals more than following a standard healthy diet. In this study, people starting metformin followed either a personalized diet or a standard low fat, high-fiber diet for six months. Both groups showed similar improvements in blood sugar, body weight, and health markers.
Zehra I. Uluturk, Anastasia Godneva, Sienna Walsh, Mallory Ledger, Eliza Chalmers, Jennifer R. Snaith et al. Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial. // Communications Medicine. – 2026. – DOI: 10.1038/s43856-026-02009-3. – URL: https://www.nature.com/articles/s43856-026-02009-3
Zehra I. Uluturk, Anastasia Godneva, Sienna Walsh, Mallory Ledger, Eliza Chalmers, Jennifer R. Snaith, Tien-Ming Hng, Renee Richens, Krisztina Toth, Jennifer Evans, Jian Tan, Laurence Macia, Mark Danta, Eran Elinav, Eran Segal, Jerry R. Greenfield, & Dorit Samocha-Bonet (2026). Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial. Communications Medicine. https://doi.org/10.1038/s43856-026-02009-3
Zehra I. Uluturk, et al. “Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial.” Communications Medicine, 2026. doi:10.1038/s43856-026-02009-3.
@article{Uluturk2026,
title = {Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial},
author = {Uluturk, Zehra I. and Godneva, Anastasia and Walsh, Sienna and Ledger, Mallory and Chalmers, Eliza and Snaith, Jennifer R. and Hng, Tien-Ming and Richens, Renee and Toth, Krisztina and Evans, Jennifer and Tan, Jian and Macia, Laurence and Danta, Mark and Elinav, Eran and Segal, Eran and Greenfield, Jerry R. and Samocha-Bonet, Dorit},
journal = {Communications Medicine},
year = {2026},
doi = {10.1038/s43856-026-02009-3},
url = {https://www.nature.com/articles/s43856-026-02009-3}
}
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02013-7 The authors identify the mitochondrial RNA methyltransferase, NSUN4 as a potential therapeutic target in intrahepatic cholangiocarcinoma, with...
Communications Medicine, Published online: 18 November 2026; doi:10.1038/s43856-026-01992-x ED Summary: O’Connor et al. use a patient-derived organoid co-culture platform to evaluate engineered bacterial therapies for colorectal cancer...
Communications Medicine, Published online: 17 November 2026; doi:10.1038/s43856-026-02012-8 Macrophage Slfn4 attenuates colonic inflammation and tumorigenesis through Rac1-dependent phagocytosis and oxidative burst
Communications Medicine, Published online: 16 November 2026; doi:10.1038/s43856-026-01727-y Ozawa et al. simulated the impact of misinformation in Canada on individuals delaying and refusing vaccination during the COVID-19 pandemic....
Communications Medicine, Published online: 14 November 2026; doi:10.1038/s43856-026-01987-8 Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either...